Eli Lilly Taltz-Zepbound Trial Shows Dual Efficacy; Fund Increases Stake 45%
Eli Lilly's Phase 2 trial combining Taltz and Zepbound achieved substantial skin clearance in moderate-to-severe psoriasis alongside meaningful weight reduction, marking the first dual-indication biologic therapy. Dempze Nancy E raised its stake by 45% to a $3.06 million position, signaling renewed institutional confidence ahead of key regulatory milestones.
1. Landmark Taltz-Zepbound Phase 2 Trial
Eli Lilly's Phase 2 trial combined its interleukin-17 inhibitor Taltz with GLP-1 analog Zepbound in moderate-to-severe psoriasis patients with obesity. Results demonstrated substantial skin clearance rates alongside meaningful weight reduction at 24 weeks, suggesting a first-in-class dual-indication therapy.
2. Institutional Stake Increase
In its latest Form 13F filing, Dempze Nancy E increased its Eli Lilly holding by 45% during the third quarter, acquiring an additional 1,243 shares to reach a $3.06 million position. This upsized stake reflects growing investor confidence in the company's pipeline.
3. Implications for Pipeline and Valuation
The dual efficacy data could expand Lilly's biologics portfolio into metabolic indications and support premium pricing, boosting long-term revenue potential. Combined with institutional backing, these developments may positively influence valuation multiples ahead of regulatory submissions and label expansions.